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Age-related macular degeneration is the leading cause of blindness in industrialized nations, 
affecting over 10 million Americans.  The most severe form of macular degeneration, the 
‘wet’ form, is caused by growth of abnormal vessels which leak excessive fluid under the 
retina, damaging the macula and leading to loss of sharp, central, color vision.  Vascular 
endothelial growth factor (VEGF) is a major factor that drives vasoproliferative diseases such 
as macular degeneration, and antibodies to VEGF are a mainstay of treatment.  In this issue 
of Circulation,
1
 Bucher and colleagues identify tetraspanin Tspan12 as a therapeutic target 
for retinal vascular proliferation, and they invent a Tspan12-targeting therapy. 
 
The retinal vasculature is uniquely adapted to supply oxygen and nutrients to photoreceptor 
cells without blocking in-coming light.  However, these specialised features also make the 
retinal vasculature susceptible to vasoproliferative retinopathy, which is the aberrant growth 
of new blood vessels and breakdown of their barrier function.
2
  Vasoproliferative 
retinopathies are driven by VEGF, a key regulator of physiological and pathological 
angiogenesis.  VEGF production is driven primarily by the hypoxia-inducible factor (HIF) 
family of transcription factors.  VEGF stimulates angiogenesis by interacting with its 
receptors VEGFR1 and VEGFR2, which in turn activate intracellular signaling cascades such 
as the RAS-RAF-MAPK pathway, triggering endothelial migration and proliferation.  VEGF-
induced VEGFR2 signaling also increases vascular permeability by separating VE-cadherin 
complexes and intercellular adhesion junctions.  The most effective treatment for 
vasoproliferative retinopathies is anti-VEGF therapy delivered by periodic intravitreal 
injections.  However, the lack of response in some patients, and relapses of 
neovascularisation and edema between treatments, indicates the clinical need for novel 
treatments.
2
 
3 
 
In the current issue of Circulation,
1
 Bucher and colleagues discovered that tetraspanin 
Tspan12 is a new therapeutic target for vasoproliferative retinopathies.  The tetraspanins are a 
superfamily of 33 integral membrane with four transmembrane regions.  Tetraspanins interact 
with specific partner proteins and regulate their intracellular trafficking and/or lateral 
diffusion and clustering at the cell surface.
3, 4
  On endothelial cells, for example, tetraspanin 
CD151 is important for angiogenesis, potentially by promoting signaling through its laminin-
binding integrin partner proteins.  In addition, tetraspanins CD9, CD63 and CD151 promote 
leucocyte capture during inflammation by clustering and forming ‘sticky platforms’ of the 
adhesion molecules intercellular adhesion molecule-1 (ICAM-1), P-selectin and vascular cell 
adhesion molecule-1 (VCAM-1), respectively.
5
  However, a substantial proportion of the 33 
human tetraspanins have not been functionally characterized in terms of regulation of specific 
partner proteins at the molecular level.  This is in part due to a lack of effective antibodies to 
these tetraspanins. 
In recent advances to the tetraspanin field, super-resolution imaging has shown that 
tetraspanins exist as nanodomains on the cell surface that comprise clusters of approximately 
10 tetraspanins of a single type.
6
  Moreover, the first full-length crystal structure of a 
tetraspanin, CD81, reported last year,
7
 revealed a cone-shaped appearance with a cholesterol-
binding cavity within the transmembrane regions (Figure 1).  Molecular dynamics 
simulations suggest that removal of the cholesterol may induce a striking conformational 
change in which the large extracellular region swings upwards, providing a potential 
mechanism by which tetraspanins could regulate partner proteins by acting as molecular 
switches.
7
  While this is unproven and based on just one tetraspanin structure, it nevertheless 
raises the exciting possibility that tetraspanins could be therapeutically targeted by small 
molecules that affect the cholesterol-binding cavity, or antibodies/small molecules that lock 
tetraspanins into a particular conformation. 
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In 2009, Junge and colleagues reported the first characterization of Tspan12-deficient 
mice and showed Tspan12 to be important for development of the retinal vasculature by 
promoting β-catenin signaling,8 an important pathway in embryonic development and in adult 
health and disease.  At the molecular level, Tspan12 appears to promote multimerization of 
the Norrin receptor Frizzled-4 (FZD-4)
8
 and interaction between FZD4 and its co-receptor 
low-density lipoprotein receptor-related protein 5 (LRP5) (Figure 1).
9
  In response to Norrin, 
the resulting intracellular signal stabilizes the multi-functional cytoplasmic protein β-catenin, 
which can then translocate to the nucleus to act as a transcriptional co-activator and turn on 
the expression of target genes
10
 (Figure 1).  Based on their observations in mice, Junge and 
colleagues speculated that mutations in human Tspan12, like existing mutations in FZD4, 
LRP5 and Norrin, might lead to the blinding disease familial exudative vitreoretinopathy.
8
  
This was proved correct a year later, with the identification of disease-causing Tspan12 
mutations.
11, 12
  It is worth noting that Tspan12 expression in the retina is restricted to 
endothelial cells,
8
 but in the rest of the body expression is more widespread and Tspan12 on 
epithelial cells and fibroblasts has been implicated in cancer progression via FZD4/LRP5-
mediated β-catenin signaling.9, 13 
In the present study, Bucher and colleagues aimed to generate anti-Tspan12 
antibodies and test whether these could reduce FZD4/LRP5-mediated β-catenin signaling and 
so be used as a treatment for vasoproliferative retinopathy.
1
  Historically, attempts to generate 
new tetraspanin antibodies have often proved unsuccessful, possibly due to the small size of 
tetraspanins and high degree of protein sequence identity between human and mouse (98% 
for Tspan12).  The Bucher approach to this problem was novel and innovative.
1
  A 48 amino 
acid peptide encompassing the variable region of Tspan12 was generated and used as a target 
antigen.  This variable region forms part of the large extracellular region, contains all six of 
the structurally-important cysteine residues, is relatively divergent in sequence between 
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tetraspanins and typically mediates interactions with partner proteins.
3
  A phage library of 
approximately 10
9
 human antibodies was then screened against the peptide.  This yielded six 
high-affinity antibodies.  One of these was definitively shown to recognize full-length 
Tspan12 by flow cytometry and immunofluorescence microscopy, using Tspan12-over-
expressing and Tspan12-knockdown cells as key controls.
1
  In future, it will be interesting to 
determine whether this approach will be applicable to other tetraspanins. 
The chosen Tspan12 antibody was found to have only a modest inhibitory effect on 
primary human umbilical vein endothelial cell function in vitro, using assays for migration 
and cell-cell adhesion.
1
  However, β-catenin expression was substantially reduced by 
antibody treatment, suggesting inhibition of β-catenin signaling.  The mechanism appears to 
involve disruption of Tspan12 interaction with FZD4, as measured by a modest reduction in 
co-immunoprecipitation of the proteins from transfected cells.
1
  While this is an artificial 
system, it may actually under-represent the true disrupting effect of the Tspan12 antibody, 
since much of the Tspan12-FZD4 complex may be intracellular and so unaffected by 
antibody treatment.  Tetraspanin antibody-mediated disruption of tetraspanin/partner 
interactions is not without precedent, since a CD151 antibody can impair laminin-binding 
integrin function by disrupting the CD151-integrin interaction.
14
  Nevertheless, to support the 
proposed mechanism of Tspan12 antibody action, future studies would benefit from 
fluorescence-based imaging methods that can measure protein-protein interactions in living 
cells in real time. 
 To investigate the therapeutic potential of their Tspan12 antibody, Bucher and 
colleagues used two mouse vascular retinopathy models, the oxygen-induced retinopathy 
model and the very low density lipoprotein receptor (VLDLR) knockout model.
1
  Oxygen-
induce retinopathy is the most widely used model for disease of the inner retinal vasculature, 
through which light must pass to reach the photoreceptor cells.  In this model, mice are 
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subjected to 75% oxygen from 7 to 12 days of age, which suppresses VEGF expression in the 
retina with consequent loss of blood vessels.  Upon re-exposure to normal air, the retina 
suffers relative hypoxia due to the lack of blood vessels.  The resulting high-level expression 
of VEGF causes vessel overgrowth and characteristic vascular tufts which are maximal on 
day 17 of age, before this repairs during the following several days.  In this model, 
intravitreal injection of Tspan12 antibody at day 12 of age reduced aberrant vessel 
overgrowth at day 17 by approximately one third, whilst promoting recovery of the lost blood 
vessels.
1
  Thus the antibody modulates vessel growth rather than functioning as an anti-
angiogenic.  The second model was the VLDLR knockout mouse, in which neovascular tufts 
develop from the outer retinal vessels that supply the over-lying photoreceptor cells.  Similar 
to its efficacy in the previous model, intravitreal injection of the Tspan12 antibody reduced 
neovascular tuft formation by approximately one third.
1
 
 The gold standard treatments for vascular retinopathies are anti-VEGF agents such as 
Aflibercept, a clinically-approved recombinant protein derived from VEGF receptors 1 and 2 
that neutralizes VEGF via high-affinity binding.  In their concluding experiments, Bucher and 
colleagues used the oxygen-induced retinopathy model to show that co-treatment with 
Aflibercept and Tspan12 antibody doubled the efficacy of either treatment alone.
1
  Titration 
experiments further showed that relatively low dose Aflibercept, in combination with 
Tspan12 antibody, is an effective treatment without inducing negative side-effects on retinal 
function that are evident with higher doses of Aflibercept.
1
 
 In summary, this exciting study will be an ‘eye-opener’ for ophthalmologists, 
prompting clinical trials to assess anti-VEGF and Tspan12 antibody combination therapy for 
vascular retinopathies such as age-related macular degeneration and diabetic retinopathy.  
This study may also galvanize research into the molecular mechanism by which Tspan12 
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regulates FZD4, and in particular whether the recently-proposed conformational change in 
tetraspanins could impact on FZD4/LRP5-induced β-catenin signaling. 
 
 
 
 
Figure 1.  Hypothetical model to show the role of Tspan12 in Norrin-induced 
FZD4/LRP5/β-catenin signaling and inhibition by the Tspan12 antibody. 
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